Trilok Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 1.50 M
as on 16-11-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 55.45 Cr
as on 16-11-2024
- Satisfied Charges ₹ 30.76 Cr
as on 16-11-2024
- Revenue -5.13%
(FY 2023)
- Profit -13.40%
(FY 2023)
- Ebitda -3.89%
(FY 2023)
- Net Worth 49.47%
(FY 2023)
- Total Assets 29.65%
(FY 2023)
About Trilok Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company currently has active open charges totaling ₹55.45 Cr. The company has closed loans amounting to ₹30.76 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rajesh Nandwani and Manav Nandwani serve as directors at the Company.
- CIN/LLPIN
U51100MP2019PTC049994
- Company No.
049994
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Company Details
- Location
Jabalpur, Madhya Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Trilok Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajesh Nandwani  | Director | 05-Nov-2019 | Current |
| Manav Nandwani | Director | 05-Nov-2019 | Current |
Financial Performance of Trilok Pharma.
Trilok Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5.13% decrease. The company also saw a substantial fall in profitability, with a 13.4% decrease in profit. The company's net worth Soared by an impressive increase of 49.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Trilok Pharma?
In 2023, Trilok Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
_PRIVATE_LIMITED.webp)
- Rabs Buildcon Private LimitedActive 12 years 10 months
Rajesh Nandwani and Manav Nandwani are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 29 Nov 2023 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 31 Mar 2022 | ₹45.00 Cr | Open |
Hdfc Bank Limited Creation Date: 04 Dec 2021 | ₹4.50 M | Open |
How Many Employees Work at Trilok Pharma?
Unlock and access historical data on people associated with Trilok Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Trilok Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Trilok Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
